INTRODUCTION
Primary open angle glaucoma (OAG) is a multi-factorial optic neuropathy characterized by progressive retinal ganglion cell death and associated visual field loss. Glaucoma prevalence is 0.7% among 40-49 year olds and rises over subsequent decades to 7.7% amongst those over 80 years of age. 1 Due to the aging of the United States population, the number of patients with OAG is expected to increase by 50% to 3.36 million in the year 2020. 2 OAG therefore represents an emerging disease with increasing cost and negative visual function impacts; yet our understanding of OAG risk factors and treatments are not fully apparent.
The only treatable risk factor for glaucoma is elevated intraocular pressure (IOP). Despite the medical lowering of IOP, however, some glaucoma patients continue to experience disease progression and subsequent irreversible blindness. For instance, in the early manifest glaucoma trial (EMGT) the disease progression rate in the treatment group was 45% as compared to 62% in the control arm. 3 In the collaborative initial glaucoma treatment study (CIGTS) substantial visual field (VF) loss occurred in 10-13.5% of participants during 5 years of followup. 4 Specifically, increased incidence of visual field deterioration occurred with older age (increased risk of VF loss by 40% every 10 years), race (nonwhites had a 50% increased risk relative to whites) and diabetes (59% increased risk relative to non-diabetic patients). 4 In a similar manner, 20% of normal tension glaucoma (NTG) patients show continued visual field loss even after 5 years of IOP reduction treatment. 5 Although IOP is still considered the only OAG risk factor, it is clear that glaucoma is a complex disease that is not prevented or cured by using only IOP reducing therapies in all patients. Among the other OAG risk factors, compromised ocular blood flow and faulty vascular autoregulation continue to emerge as possible contributors to OAG disease pathophysiology. Vascular related OAG risk factors have been found in prospective, retrospective and large epidemiological studies throughout the world. Growing evidence suggests that glaucoma patients have reduced blood flow to the retina, choroid and optic nerve. It is unclear whether there is a primary contributing vascular component that promotes damage to the optic nerve and retinal ganglion cells (as well as aqueous humor dysregulation), if the OAG vascular component is secondary to increased IOP, or if it represents a combination of the two including impaired autoregulation within the OAG population. 6 Several of the most common vascular risk factors which may be related to OAG disease include: aging, systemic blood pressure, nocturnal hypotension, ocular perfusion pressure, migraine, disk hemorrhage, diabetes and directly assessed reductions of ocular blood flow. Each of these topics will be reviewed in detail within this manuscript.
AGING
In population-based studies age is reported as an important risk factor for glaucoma. 7 Age leads to many changes that can contribute to glaucoma which include vascular and mechanical changes as well as small increases in IOP. 8 Mean IOP and cupto-disc ratio has been associated with age, especially in OAG patients over 75 years of age. 9 Similarly, reduction of vascular function with age is well known and reduced choroidal and retrobulbar blood flow have been reported to occur with increasing age. 10 The optic nerve head (ONH) is primarily perfused by the short posterior ciliary arteries with some contribution from the retinal arterioles to the superficial nerve fiber layer. Studies in normal healthy individuals have shown reductions in blood flow to occur to the optic nerve with increasing age. 11, 12 Specifically, decreased blood flow was observed with age in the area of the neuroretinal rim and lamina cribrosa. 13 However, aging also contributes to mechanical weakness in the area of the lamina cribrosa that can be further compromised by increased IOP. Over time there is an increase in elastin fiber coupled with increases in the connective tissue thickness of the optic nerve 14 and increased thickness of the lamina cribrosa. 15 Furthermore, there is a decrease in number of axons and thinning of the nerve fiber layer. 16 The overall effects of aging are complex and hard to individually separate. The loss of normal vascular function with age seems to contribute to the overall age-related breakdown of eye structures and function. These age-related changes may disrupt the normal vascular regulation of ocular blood flow. For instance, vascular autoregulation dysfunction in response to postural induced changes in ocular perfusion pressure has been shown in glaucoma patients compared to healthy controls. 17 Autoregulation of blood flow being impaired alone and/or in combination with elevated IOP may be compounding the damage to the optic nerve and contributing to visual field loss in OAG.
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Systemic Blood Pressure and Perfusion Pressure
Systemic hypertension 19 and hypotension 20 have both been reported as potential risk factors in glaucoma. It has been suggested that chronic hypertension may cause microvascular damage as a result of increased peripheral resistance in the small vessels and atherosclerosis changes, while hypotension may chronically reduce local ocular perfusion. It is important to understand that IOP and blood pressure determine ocular perfusion pressure (OPP) as OPP equals 2/3 (mean arterial pressure) minus IOP. 21 This is also often further broken down into systolic and diastolic perfusion pressures. Patients with systolic blood pressure higher than 130 mmHg or diastolic perfusion pressure (diastolic blood pressure minus IOP) lower than 30 mmHg were reported to have higher risk for OAG. 22 In the Egna-Neumarkt study 23 a positive correlation was found between systemic blood pressure and diagnosis of OAG as well as to IOP. Reduced diastolic perfusion pressure below 55 mmHg is emerging as an important risk factor for OAG. Specifically, Hulsman et al 24 recently reported an association between high tension glaucoma and high pulse pressure accompanied by arterial stiffness as well as with low diastolic perfusion pressure in patients receiving treatment for systemic hypertension. The increased vascular stiffness may contribute to the impaired autoregulation in glaucoma patients. Patients with increased diastolic blood pressure of 85 mmHg or higher had a higher risk of NTG and surprisingly patients with low diastolic perfusion pressure had a significantly lower risk of NTG. Importantly, perfusion pressure fluctuations have been recently shown to be related to visual field progression. 25 The information available on blood pressure and OAG continues to be complex, and often appears different among differing races. A population-based study on Hispanic subjects did not find a clear correlation between systemic hypertension and prevalence of OAG but did find that the lower the diastolic perfusion pressure the more likely the subject was to have OAG. 26 Importantly, those with a perfusion pressure lower than 50 mmHg had a 4 times greater risk of OAG than those with a perfusion pressure of 80 mmHg. 26 The Barbados Incidence Study of Eye Diseases (BISED) 27 in a large, predominantly African-origin population, found that persons with hypertension had a statistically significant decreased risk of OAG. It can be hypothesized that higher blood pressure in the early stages can protect the optic nerve by maintaining the ocular perfusion pressure. OAG incidence was highest with low ocular perfusion pressure; lower systolic perfusion pressure more than doubled the relative risk (RR) and lower diastolic perfusion pressure (DPP) (<55 mmHg) more than tripled the RR of OAG. McLeod et al 28 found a positive correlation between change in IOP from one year to the other and the change in systemic blood pressure during the same period. The Rotterdam study 29 reported a similar association between systolic and diastolic blood pressure and IOP. Furthermore, hypertension was associated with high tension glaucoma but not with NTG. NTG patients were more likely to have decreased blood pressure, perhaps further emphasizing the role of defective perfusion pressures in this form of glaucoma. 30, 31 Within the multitude of differing results on blood pressure and OAG, understanding how OAG patients may differ from healthy subjects in response to blood pressure changes may hold the key. As abnormal autoregulation has been reported in glaucoma patients, we need to answer whether a blood pressurerelated decrease in ocular perfusion pressure has a direct effect on ocular blood flow. Gherghel et al have reported a lower mean blood pressure and lower end diastolic velocity in the central retinal artery (CRA) in patients with progressing OAG compared to controls. 32 Mean perfusion pressure correlated positively with end diastolic velocity in the ophthalmic artery (OA) and CRA and negatively with Pourcelot's resistive index in the OA and CRA. 32 This suggests that OAG patients' ocular blood flow is compromised during changing blood pressure, IOP and perfusion pressure while healthy individuals can maintain constant ocular circulation.
Nocturnal Hypotension
It is well-established that circadian rhythms play an important role in maintaining homeostasis in the human body. In that capacity, blood pressure may be involved in OAG progression, not due to the overall level of blood pressure, but to an abnormal reduction in blood pressure during non-waking hours. It has been known for over four decades that IOP 33 varies throughout the day, but not until more recently has it been shown that other factors affecting the eye such as systemic blood pressure, 34 ocular perfusion pressure 35 and ocular blood flow 36 also follow circadian patterns. Studies indicate that blood pressure normally decreases at night, during sleep, to levels 10 to 20 percent below the diurnal average. 37, 38 It is also thought that perfusion instability, rather than a steady reduction of ocular blood flow, might contribute to glaucomatous optic neuropathy. 39 Given the known circadian nature of systemic arterial pressure, numerous studies in recent years have attempted to associate glaucoma risk with nocturnal variations in blood pressure.
Hayreh et al 40 performed 24-hour blood pressure monitoring on 166 white patients with either anterior ischemic optic neuropathy, NTG or OAG. Results showed that NTG patients had significantly lower diastolic blood pressure at night and a significantly greater mean decrease in diastolic blood pressure at night compared to patients with anterior ischemic optic neuropathy. Of particular interest was their finding of an apparent interaction between systemic hypertension, deterioration of visual field and nocturnal blood pressure. Their results showed that among patients taking systemic hypotensive medication, the nocturnal blood pressure dips were significantly larger for those with progressing visual field loss than compared to those who had clinically stable visual fields. This progressing visual field group also showed a significantly lower mean minimum nighttime systolic blood pressure as compared to the stable group. A more recently published paper 41 also suggests an association between nocturnal blood pressure levels and progressing visual field damage. Twentyfour hour ambulatory blood pressure readings were taken for three groups: NTG, OAG and age-matched normal controls. The glaucoma patients with progressing visual field loss had significantly lower mean nighttime blood pressure and significantly greater mean decrease in nighttime blood pressure than the patients with stable visual fields.
These data indicate a possible association between systemic blood pressure and glaucoma; however the effect this factor may have on ocular circulation is not fully known. As IOP, blood pressure and perfusion pressure are now known to fluctuate during the day and night, previously unseen mild chronic hypo-perfusion of the ONH and retina during these fluctuations may contribute to OAG pathophysiology.
Other Vascular Risk Factors: Migraine, Disk Hemorrhage, Diabetes
Migraine as a disease may reflect a more generalized vasospastic tendency that can further affect ocular blood flow. For instance, migraine has been reported to influence the survival time of patients with NTG. The reported risk ratio of patients with migraine to experience disease progression was 2.58 times greater than patients without migraine. 42 Migraine is significantly more common in patients with NTG compared with control subjects and patients with high-pressure glaucoma. 43 In the NTG study, untreated female patients with migraine visual function deteriorated faster than those without migraine. 47 Migraine may therefore represent an larger vascular problem that appears to contribute to OAG disease.
Disk hemorrhages have also been positively related to NTG. Patients with presence of disk hemorrhage at baseline had 2.7 times greater risk to progress than patients without hemorrhage at baseline. 42 Rasker et al 44 reported that 80-89% of glaucoma patients with optic disc hemorrhages experienced glaucomatous progression as opposed to 32% of patients who did not have disc hemorrhage (mean follow-up of 9 years). Further, OAG patients with diabetes and those using aspirin were reported to have a higher risk of having optic disc hemorrhage. 45 The early manifest glaucoma trial also reported that patients with frequent disc hemorrhages had increased progression of glaucoma. 46 It was also reported that NTG patients without baseline disc hemorrhage responded better to treatment then patients with baseline disc hemorrhage. 47 Diabetes, a disease with many vascular complications, has been reported to be related to glaucoma. 48 However the evidence for diabetes as a contributing factor in OAG pathology is currently lacking. Population-based studies, such as the Baltimore eye survey, 49 the Barbados eye study 7 and the Rotterdam study 50 have failed to support an association between diabetes and glaucoma. Due to the multitude of vascular changes in diabetes, more prospective evidence is required before definitive conclusions can be made.
Directly Assessed Reductions of Ocular Blood Flow
Reduced ocular perfusion may be secondary to IOP elevation or represent a primary insult to the optic nerve in glaucoma. Chronic ocular ischemia may be due to faulty vascular autoregulation and the inability of the vasculature to overcome elevated IOP to maintain adequate perfusion. Regardless, chronic optic nerve ischemia has been shown to induce retinal ganglion cell loss independent of IOP. 51 The cascade of events involving reduction of ocular blood flow leading to retinal ganglion cell apoptosis are shown in Figure 1 . 52 There is a multitude of various small prospective studies which have demonstrated blood flow deficiencies of OAG patients in the retinal, 53 choroidal 54 and retrobulbar [55] [56] [57] [58] circulations. Reductions in ocular blood flow have also been shown to correspond with areas of glaucomatous visual field loss. 59 The studies and evidence mentioned above utilize many different ocular blood flow imaging technologies in an attempt to reveal blood flow deficits in glaucoma. Each imaging technology has various limitations and is tissue-specific within Fig. 1 the eye's vasculature and is discussed in great detail elsewhere. 60 The overwhelming amount of evidence from the various imaging techniques in the retinal, choroidal and retrobulbar vascular beds, however, points to ischemia's role in OAG pathophysiology. Moreover, it is important to consider that the direct and indirect evidence for ocular ischemia in OAG represents a surrogate for retinal metabolism and oxygenation.
The direct measurement of retinal tissue oxygenation would reveal the true nature of ischemia's impact on retinal ganglion cell health and function. Currently, ocular blood flow investigations suggest that retinal tissue may be experiencing a lack of oxygenation and this hypoxia is contributing to OAG disease. New and emerging metabolic assessment tools may help reveal how reductions in ocular blood flow and ocular tissue hypoxia are related. 61 Specifically, one study by Michelson et al measured the oxygen saturation in retinal arterioles and venules in patients with glaucomatous optic neuropathy by imaging spectrometry. 62 In all examined eyes, the arteriolar oxygen saturation and the retinal arterio-venous differences in oxygen correlated significantly with the patient's rim area. Eyes with NTG but not OAG showed significantly decreased arteriolar oxygen saturation. These metabolic assessment tools, while still undergoing improvements, 63 may provide the next step in specifically assessing retinal hypoxia, possibly as a result of ocular ischemia.
Summary
As of today, IOP remains the only treatable risk factor in glaucoma patients. We currently have a variety of topical and systemic medications, and various surgeries to effectively lower a patient's IOP. Although a large percentage of patients respond to IOP lowering treatment showing slower deterioration of their visual function, we still face two challenging groups of patients. The first group, are patients that do not respond well to IOP reduction despite medical and surgical treatment and the other group are patients that continue to deteriorate despite wellcontrolled IOP. Understanding these risk factors that can be responsible for the continued deterioration while addressing and manipulating the risk factors may improve the outcome of OAG patients. Vascular risk factors, including faulty autoregulation of the ocular vasculature, continue to emerge as important considerations in glaucoma. Early pilot data suggests that vascular abnormalities are related to visual field and optic nerve damage. 64, 65 These pilot studies suggest that compromised ocular blood flow may occur before glaucomatous changes are detectable from visual field testing. It is important to note, however, that only after a longitudinal, comprehensive and statistically justified study shows that glaucomatous disease progression is related to ocular blood flow can we be confident in changing treatment direction to vascular risk factors. It remains to be seen if changing possible vascular risk factors will indeed change patients' structural as well as functional outcomes. Future treatment approaches should target increasing ocular blood flow, elevating and maintaining ocular perfusion pressure, moderating diurnal fluctuations in blood pressure, IOP and perfusion pressure and providing direct neuroprotection.
